Bristol Myers Squibb | Sustainability Performance
Develops and markets pharmaceuticals for various medical conditions, including oncology and immunology.
1858
United States
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3144
Overallⓘ#626
in United Statesⓘ#76
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
TargetsSDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Critical
Leading
Aligned
Critical
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
7.4
B/M 13.9
40.8
B/M 111.2
30.5
B/M 65.5
0.2
B/M 1.1
Powered by illuminem and GIST Impact
Controversy level
- Bristol Myers Squibb paid USD 515 million DOJ False Claims Act settlement over illegal marketing of antipsychotic Abilify and other drugs for unapproved uses.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.